Anzeige
Mehr »
Login
Montag, 25.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
500% Potenzial: Warum Analysten von diesem Uran-Explorer begeistert sind!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
614 Leser
Artikel bewerten:
(2)

ConvaTec Enhances Innovation Management with Anaqua

Finanznachrichten News

Anaqua's AQX platform to help global medical products group protect and optimize its valuable IP portfolios

LONDON, Sept. 21, 2021, the leading innovation and intellectual property management technology provider, today announced that global medical products and technologies group ConvaTec will use Anaqua's AQX platform to help more effectively manage their valuable patent and trademark portfolios.

The agreement further strengthens Anaqua's position in the medical solutions markets, with a growing number of clients from these sectors collaborating with Anaqua as their preferred IP management provider.

With operations in more than 100 countries, ConvaTec is a global medical and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence care, critical care, and infusion care. ConvaTec products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care.

Christina Allegrini, Vice President, Deputy General Counsel & Global Head of Intellectual Property at ConvaTec, said: "Our company vision is to pioneer trusted medical solutions to improve the lives we touch. As part of this, one of our key strategic pillars is to innovate in our work and solutions, supported by increased investment in R&D. Therefore, it is critically important that we manage our innovation and IP effectively and efficiently - and Anaqua will help ensure we do that."

ConvaTec will use Anaqua's AQX platform for patent and trademark management, annuities and renewals (in conjunction with Anaqua Services), and patent analytics through integration with Anaqua's AcclaimIP.

Bob Romeo, CEO of Anaqua, said: "We are proud to be working with and supporting ConvaTec, a company driven by innovation to better serve people around the world in need of advanced medical care. For our part, we look forward to helping ConvaTec protect their innovation and IP management needs. We are also delighted to add another global company to our growing portfolio of clients in the healthcare and life sciences sectors."

About Anaqua
Anaqua, Inc. is a premium provider of integrated intellectual property, or on LinkedIn.

About ConvaTec
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. Headquartered in the UK, the company has operations in more than 100 countries and almost 10,000 employees worldwide. ConvaTec products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit convatecgroup.com.

Company Contact:
Amanda Hollis
Associate Director, Communications
Anaqua (https://www.anaqua.com/?utm_medium=press&utm_source=wire&utm_campaign=ConvaTec)
617-375-2626
ahollis@Anaqua.com (mailto:ahollis@Anaqua.com)


© 2021 GlobeNewswire (Europe)
5 heiße Wetten für den Jahresendspurt!
Nach dem unerwartet schnellen Ende der US-Wahlen mit dem Sieg des republikanischen Kandidaten Donald Trump fackelten die Aktien- und Krypto- Märkte ein wahres Kursfeuerwerk ab und bliesen zur Jahresendrallye.

Im aktuellen kostenlosen Report beleuchten wir 5 aussichtsreiche Unternehmen, die das Fundament besitzen, in den nächsten Monaten den breiten Markt zu schlagen.

Seien Sie dabei!

Fordern Sie jetzt unseren brandneuen neuen Spezialreport an und erfahren Sie, welche Aktien aufgrund ihrer Bewertung sowie charttechnischen Situation das Potenzial zu einer Outperformance besitzen.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.